Niagen Bioscience (NASDAQ:NAGE) Rating Increased to Strong-Buy at Wall Street Zen

Key Points

• Niagen Bioscience has been upgraded to a "strong-buy" rating by Wall Street Zen, reflecting increased confidence in the company's stock.
• Several analysts have raised their target prices for Niagen, with HC Wainwright setting it at $12.00 and Roth Capital at $23.00, indicating a strong bullish sentiment among investors.
• In its most recent earnings report, Niagen exceeded expectations with a revenue of $31.12 million and an EPS of $0.04, highlighting the company's strong financial performance.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) was upgraded by Wall Street Zen from a "buy" rating to a "strong-buy" rating in a research report issued on Saturday.

Several other equities analysts have also issued reports on the company. HC Wainwright boosted their target price on Niagen Bioscience from $11.00 to $12.00 and gave the stock a "buy" rating in a research report on Monday, August 11th. Roth Capital restated a "buy" rating and set a $23.00 target price (up from $10.00) on shares of Niagen Bioscience in a research report on Friday, June 6th. Finally, Canaccord Genuity Group boosted their target price on Niagen Bioscience from $13.00 to $16.00 and gave the stock a "buy" rating in a research report on Tuesday, June 10th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $13.42.

Niagen Bioscience Trading Up 3.2%

Niagen Bioscience stock opened at $10.02 on Friday. The firm has a market capitalization of $799.13 million, a P/E ratio of 47.72 and a beta of 2.12. Niagen Bioscience has a 1 year low of $3.10 and a 1 year high of $14.69. The business has a 50-day moving average of $11.57 and a 200-day moving average of $8.43.

Niagen Bioscience (NASDAQ:NAGE - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.02. The company had revenue of $31.12 million during the quarter, compared to analyst estimates of $28.55 million. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%.

Hedge Funds Weigh In On Niagen Bioscience

Several institutional investors and hedge funds have recently modified their holdings of NAGE. State of Wyoming acquired a new position in shares of Niagen Bioscience in the 4th quarter valued at approximately $39,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of Niagen Bioscience in the 4th quarter valued at approximately $53,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Niagen Bioscience in the 4th quarter valued at approximately $67,000. ProShare Advisors LLC acquired a new position in shares of Niagen Bioscience in the 4th quarter valued at approximately $74,000. Finally, Sherbrooke Park Advisers LLC acquired a new position in shares of Niagen Bioscience in the 4th quarter valued at approximately $94,000. 15.41% of the stock is currently owned by institutional investors and hedge funds.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.